Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management

Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management

It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process, which includes conducting an accurate clinical...

Full description

Bibliographic Details
Main Authors: Alessandra Zannella, Massimo Marignani, Paola Begini
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Viruses
Subjects:
reactivation
lymphoma
hematology
immunosuppressive therapy
prophylaxis
hepatitis B virus
occult/active/inactive carrier
Online Access:https://www.mdpi.com/1999-4915/11/9/858

Internet

https://www.mdpi.com/1999-4915/11/9/858

Similar Items